OBJECTIVES: Lymph node involvement is a key feature and an independent prognostic factor of oesophageal squamous cell carcinoma. However, an accurate and robust assay to predict the lymphatic spread of oesophageal squamous cell carcinoma is unavailable.
INTRODUCTION
Oesophageal carcinoma, including both squamous cell carcinoma and adenocarcinoma, is the eighth most commonly diagnosed cancer and the sixth most common cause of death from cancer worldwide in 2008 [1] . The incidence and mortality rates of oesophageal cancer in China are 16.7 and 13.4 per 100 000, respectively, and squamous cell carcinoma accounts for the major histotype [2] . Lymph node metastasis is observed more frequently in oesophageal cancer than in other gastrointestinal tract cancers, which significantly contributes to such a high mortality rate despite successful surgical resections [3] . Currently, endoscopic ultrasonography, computed tomography (CT) or 18 F-fluoro-2-deoxyglucose positron emission tomography sometimes provides false-positive results in predicting the preoperative lymph node status of oesophageal squamous cell carcinoma patients. Histological examination of resected lymph nodes remains the gold standard [4] . In order to precisely assess lymph node involvement prior to biopsy, it is necessary to identify sensitive biomarkers and explore robust assays.
Lymph node metastasis has attracted remarkable attention over the decades because it is a major prognostic factor for diverse tumour types [4] . Vascular endothelial growth factor-C (VEGF-C) is a ligand for the vascular endothelial growth factor receptor 3, which is essential for lymphangiogenesis. In VEGF-C knockout mice, early lymphatic endothelial cells fail to migrate from cardinal veins to form lymphatic vessels [5] . Since the induction of tumour lymphangiogenesis by VEGF-C was first discovered to promote cancer metastasis, a dedicated field has been focussed on VEGF-C expression in various human cancers and the mechanisms by which VEGF-C stimulates lymphatic metastasis. Several studies have established the connection between VEGF-C expression and lymph node metastasis in oesophageal squamous cell carcinoma. For example, Kozlowski et al. [6] suggested that serum VEGF-C levels reflect the stage of lymph node metastasis of oesophageal carcinoma. Kimura et al. [7] reported that the serum VEGF-C level is correlated with oesophageal carcinoma recurrence. A recent study indicated that the spread of tumour cells is facilitated by the expansion of lymphatic networks within the lymph node induced by VEGF-C prior to the onset of metastasis [8] . In the present study, we sought to test the correlation between serum VEGF-C and lymph node metastasis in Chinese oesophageal squamous cell carcinoma patients.
Spleen tyrosine kinase is a non-receptor tyrosine kinase and is activated upon the binding of tandem Src homology 2 domains to immunoreceptor tyrosine-based activating motifs [9] . Intensive studies have revealed that spleen tyrosine kinase plays important roles in lymphocyte development, activation of immune cells and leukaemia by regulating many signalling pathways [9, 10] . Overexpression of spleen tyrosine kinase is observed in peripheral T-cell lymphomas, chronic lymphocytic leukaemia and B-lineage acute lymphoblastic leukaemia [11] . In contrast, accumulating data also showed that spleen tyrosine kinase can function as a tumour suppressor, and that reduced spleen tyrosine kinase expression correlates with tumour metastasis and poor prognosis in breast cancer, pancreatic cancer, hepatocellular carcinoma, bladder carcinoma and melanoma [12] . However, the clinical significance of spleen tyrosine kinase in oesophageal squamous cell carcinoma is largely unknown. Chen et al. [13] showed that spleen tyrosine kinase may down-regulate VEGF-C expression through inhibiting NF-kappa B activation in breast cancer. This prompted us to examine whether spleen tyrosine kinase acts as a tumour suppressor in oesophageal squamous cell carcinoma, and whether both serum spleen tyrosine kinase and VEGF-C can be employed as biomarkers of lymph node metastasis of oesophageal squamous cell carcinoma.
MATERIALS AND METHODS

Patients eligibility
Patients were eligible if they had a histological or cytological diagnosis of middle or lower oesophageal squamous cell carcinoma. The TNM (T, primary tumor; N, regional lymph nodes; M, distant metastasis) classification of oesophageal squamous cell carcinoma was based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition. Patients should not have received prior radiotherapy, chemotherapy or blood transfusion and surgery within the last 6 months. Adequate hematological status was required, including a leucocyte count of >3.0 × 10 9 /l, absolute neutrophil count >1.5 × 10 9 /l and haemoglobin of 6.2 mmol/l or greater. Adequate hepatic and renal functions were defined as aspartate aminotransferase or alanine aminotransferase levels <2-fold the upper limit of normal, total bilirubin less than the limit of normal, and serum creatinine <130 μmol/l or creatinine clearance >60 ml/min. Patients with metastases in other organs were excluded according to CT scan, B ultrasound and bone scan. Patients with comorbidities, such as congestive heart failure, established ischaemic heart disease, cerebrovascular disease, myocardial infarction, peripheral vascular disease, active infection or significant psychiatric illness were excluded. A total of 24 healthy volunteers were recruited to the study as controls. The protocol was approved by the hospital's ethics review board. All subjects signed the written informed consent before the tests.
Clinical samples and enzyme-linked immunosorbent assays
Venous blood samples were drawn from volunteers and patients before and after surgery and kept at room temperature for 30 min to clot, followed by centrifugation for 15 min at 1000×g. Isolated serum was stored at −20°C for further analyses. Serum spleen tyrosine kinase and VEGF-C levels were measured using enzymelinked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Briefly, the enzyme-linked immunosorbent assay plates were precoated with monoclonal antibodies against human VEGF-C or spleen tyrosine kinase. VEGF-C or spleen tyrosine kinase in the serum samples was captured by the antibodies and detected through binding to horseradish peroxidase-conjugated anti-human VEGF-C or spleen tyrosine kinase polyclonal antibodies. Signals were recorded after adding the substrate and tetra methyl benzidine. Human recombinant VEGF-C or spleen tyrosine kinase was used as the standard. VEGF-C or spleen tyrosine kinase levels in the serum samples were calculated based on the standard curves generated by plotting the absorbance against the known concentrations of VEGF-C or spleen tyrosine kinase. Samples were examined in triplicates and the average was used in the data analysis.
Statistical analyses
All statistical analyses were performed using SPSS11.0 software (SPSS, Chicago, IL, USA). Data were expressed as mean ± standard deviation (SD). P-values between the two groups were calculated using Student's t-test. The results of different time points within one group were analysed using analysis of variance for repeated measures model. P-values between two time points within one group were calculated using Fisher's least significant difference (LSD) test. Pearson's correlation coefficient was used to assess the association between serum spleen tyrosine kinase and VEGF-C levels. The relationship between VEGF-C and spleen tyrosine kinase expressions regarding various clinicopathological parameters was tested for significance using the χ 2 -test. The significance between the two groups was determined using the LSD test. Receiver operating characteristic (ROC) curves were obtained for spleen tyrosine kinase and VEGF-C in order to evaluate their sensitivity and specificity as predictors of lymph node involvement. A 5% P-value was set to be statistically significant.
RESULTS
From May 2008 to June 2012, a total of 108 patients treated in the Department of Thoracic Surgery, the Third Affiliated Hospital of Kunming Medical University, were enrolled in the study. Patient characteristics are summarized in Table 1 . The median age was 64 years (range, 47-74 years), and 43.5% were women. The control group consisted of 11 females and 13 males, with a median age of 66 years (range, 51-73 years). There were no significant differences in age or sex between the patients and healthy control subjects.
In patients with middle or lower oesophageal squamous cell carcinoma, the mean serum VEGF-C level was found to be statistically higher than that in the control group (2931.0 vs 915.7 pg/ml, P < 0.05, Table 2 ). Enzyme-linked immunosorbent assays also revealed that the mean serum spleen tyrosine kinase level in the patients was dramatically reduced compared with healthy subjects (3914.0 vs 5275.4 pg/ml, P < 0.05, Table 2 ). To test whether surgical resection had any effect on VEGF-C or spleen tyrosine kinase levels, we monitored their serum concentration before and after surgery, which included primary tumour resection and lymph node dissection. The postoperative serum VEGF-C level gradually reduced and reached 1460.1 pg/ml at 2 weeks after operation, which was significantly lower than the preoperative level (P < 0.05, Table 2 ). In addition, we observed that the spleen tyrosine kinase level significantly increased up to 4818.5 pg/ml at 14 days after operation relative to the preoperative level (P < 0.05, Table 2 ). Importantly, Pearson's correlation analysis revealed that the serum spleen tyrosine kinase level was negatively correlated with the VEGF-C level in oesophageal squamous cell carcinoma patients (r = −0.453, P = 0.000, Fig. 1 ). The results suggested that patients with oesophageal squamous cell carcinoma are characterized by elevated VEGF-C and decreased spleen tyrosine kinase in serum, and that tumour resection would be beneficial for bringing their levels back to normal.
The correlation of serum VEGF-C and spleen tyrosine kinase with the clinicopathological features of the patients is presented in Table 1 . We did not find any significant correlation between serum VEGF-C or spleen tyrosine kinase and patient sex, age or histological grading (P > 0.05, Table 1 ). However, we observed that the serum VEGF-C level in N 0 cancers was 2502.9 pg/ml, 2874.3 pg/ml in N 1 , 3145.1 pg/ml in N 2 and 3574.6 pg/ml in N 3 , suggesting that elevated serum VEGF-C was correlated with the stage of regional lymph node metastasis (P < 0.05). Statistical analysis also revealed a significant difference of serum VEGF-C between N 0 and N 1 + N 2 + N 3 (P < 0.01, Table 1 ). In addition, T is recognized as an independent prognostic factor of lymph node involvement since nodal status depends on the primary tumour extension. We found that serum VEGF-C was significantly correlated with T status in patients (P < 0.05, Table 1 ). Statistical analysis also revealed the correlation between the tumour size and the serum VEGF-C level. Moreover, we discovered that decreased serum spleen tyrosine kinase was inversely correlated with tumour size, N, and T status in oesophageal squamous cell carcinoma patients (P < 0.05, Table 1 ). In addition, the sensitivity and specificity of serum VEGF-C for predicting lymph node metastasis in oesophageal squamous cell carcinoma patients were calculated by construction of a ROC (Fig. 2A) . The area under the ROC curve of VEGF-C was 0.728 ± 0.060 (95% confidence interval (CI) = 0.611-0.845, P = 0.003). A sensitivity of 98.9% and a specificity of 94.1% were obtained using a cut-off value of 1842.2 pg/ml VEGF-C. The area under the ROC curve of spleen tyrosine kinase was 0.151 ± 0.057 (95% CI = 0.038-0.263, P = 0.000). A sensitivity of 93.4% and a specificity of 94.1% were observed, choosing a cut-off value of 3555.8 pg/ml spleen tyrosine kinase (Fig. 2B) . Taken together, our data suggest that both serum VEGF-C and spleen tyrosine kinase levels could predict lymph node metastasis of oesophageal squamous cell carcinoma.
DISCUSSION
Oesophageal carcinoma is recognized as one of the most lethal of all gastrointestinal malignancies because of early lymphatic spreading. The presence of lymph node metastasis is a uniquely important prognostic factor for oesophageal squamous cell carcinoma. Both the anatomic locations and the number of involved lymph nodes predict survival reliably [14] . Thus, identifying regional lymph node status is critical in staging the disease. The oesophagus is characterized by a fully developed lymphatic drainage system, which contains a complicated lymphovascular network and abundant lymph capillaries [3] . Tumour-derived proteins, secreted molecules and even dissociated tumour cells could easily invade the lymphatic system since the thin-walled capillaries are composed of a single layer of endothelial cells. Circulating tumour cells can eventually disseminate to distal organs and form metastases [4] . This suggests that tumour metastasis could be more advanced than that detected by histological examination, which is a widely used standard method. We thought that lymphangiogenesis-related circulating molecules secreted by tumour cells might reflect tumour spreading. In addition, analysing protein levels in serum by enzyme-linked immunosorbent assays is a reliable and efficient method with less cost and damage. A precise preoperative assessment of lymph node metastasis enables surgeons to better manage radical dissection and to minimize risks of mortality. Among the variety of candidates for predicting lymph node metastasis, both VEGF-C and spleen tyrosine kinase caught our attention based on accumulating reports and our previous study of the association between them and lymph node involvement in lung adenocarcinoma [15] . VEGF-C is well studied to promote lymphangiogenesis and is investigated for its expression in variable tumours with lymphatic spreading [4] . In most solid tumours, the occurrence of lymphangiogenesis could be a biomarker for potential lymphatic metastasis and a poor prognosis [3] . Kozlowski et al. [6] reported that there was a positive correlation between elevated serum VEGF-C and tumour depth, resectability, tumour size, histological grade and lymph node metastasis in oesophageal cancers. In another study, Katsuda et al. [16] showed that expression of VEGF-C and hypoxiainducible factor 1α correlated with lymphatic invasion, indicating that hypoxia-inducible factor 1α plays a role in lymphatic invasion via the induction of VEGF-C in oesophageal squamous cell carcinoma. We observed consistent results in Chinese oesophageal squamous cell carcinoma patients that increased serum VEGF-C was correlated with lymph node metastasis, tumour size and primary tumour extension, but not with age, sex or histological grading. Moreover, significantly elevated serum VEGF-C was observed in oesophageal squamous cell carcinoma patients relative to normal controls, which was reversed upon the removal of the tumours. Our findings confirmed that serum VEGF-C is a sensitive marker for lymph node metastasis in oesophageal squamous cell carcinoma patients. Interestingly, a recent paper showed that VEGF-C expression was significantly different between the two histological types of oesophageal carcinoma. Oesophageal patients with squamous cell carcinoma and lymph node metastases had a significantly higher VEGF-C expression compared with that of patients with adenocarcinoma [17] . In 2012, Chen et al. [18] published a systematic review and meta-analysis by analysing 30 studies of 2345 patients. They concluded that high VEGF-C expression was significantly associated with poor survival in patients with oesophageal squamous cell carcinoma but not adenocarcinoma. In the future, we should expand our cohort and analyse the difference in VEGF-C expression between the two types of oesophageal carcinoma to identify the effects of cancer cell differentiation on VEGF-C secretion and lymph node metastasis.
However, the molecular mechanisms by which VEGF-C regulates lymph node metastasis are not fully understood, although in vitro studies have demonstrated that VEGF-C possesses the capability of stimulating the proliferation, migration and survival of endothelial cells [19] . Specific overexpression of VEGF-C in mouse skin resulted in increased numbers of enlarged, actively proliferating, tumour-associated lymphatic vessels during multistep skin carcinogenesis. Tumour-expressed VEGF-C also promoted active expansion of the lymphatic network and tumour metastasis to distant lymph nodes [8] . Further studies are necessary to address how VEGF-C induces lymph node metastasis in oesophageal squamous cell carcinoma.
Previously, spleen tyrosine kinase was considered a haematopoietic cell-specific signalling molecule involved in cell proliferation, differentiation and survival [11] . For example, overexpression of spleen tyrosine kinase and activation of its downstream pathways including phospholipase C gamma 2, signal transducers and activators of transcription 3 and extracellular signal regulated kinase 1/2 were observed in chronic lymphocytic leukaemia. Spleen tyrosine kinase inhibitors could reduce phosphorylation of spleen tyrosine kinase downstream targets and induce apoptosis in primary chronic lymphocytic leukaemia cells [9] . Recent studies showed that spleen tyrosine kinase is ubiquitously expressed in non-haematopoietic cells. The role of spleen tyrosine kinase as a tumour suppressor in breast cancer has been substantially investigated. The loss or reduced spleen tyrosine kinase expression in human breast cancer was associated with an increased risk of breast cancer metastasis and a higher degree of malignancy and poor prognosis [20] . In a mouse model, spleen tyrosine kinase expressing breast cancer cells formed less metastatic lesions after intravenous injection and exhibited reduced tumour growth after subcutaneous injection [21] . The tumoursuppressive activity of spleen tyrosine kinase in breast cancer cells has been associated with abnormal mitotic progression and cell death [22] . In addition, two different mechanisms controlling spleen tyrosine kinase expression have been described: hypermethylation of its promoter and alternative splicing [23] . Epigenetic silencing through hypermethylation of critical CpG islands was proposed to be involved in the loss of spleen tyrosine kinase in a significant fraction of breast tumours. More recently, a loss of spleen tyrosine kinase expression has been documented in melanoma cells [24] . A similar correlation was found in gastric cancer patients, where hypermethylation of the spleen tyrosine kinase promoter was mainly observed in patients with lymph node metastases [25] . Our data showed that oesophageal squamous cell carcinoma patients had significantly reduced serum spleen tyrosine kinase compared with normal controls, indicating that spleen tyrosine kinase may function as a tumour suppressor and that the reduction of spleen tyrosine kinase expression may play a role in the progression of oesophageal squamous cell carcinoma. However, the molecular events responsible for spleen tyrosine kinase tumour suppressor effects in oesophageal squamous cell carcinoma cells have remained completely unknown.
Statistical analysis revealed that serum VEGF-C was negatively associated with the spleen tyrosine kinase level in oesophageal squamous cell carcinoma patients, which is consistent with the observation reported in breast cancers with lymph node metastasis [13] . Overexpression of spleen tyrosine kinase in MDA-MB-231 cells significantly reduced VEGF-C mRNA transcription through inhibiting NF-kappa B activation [13] . This suggests that both serum spleen tyrosine kinase and VEGF-C are important biomarkers to evaluate lymph node metastasis. The potential spleen tyrosine kinase downstream targets include a wide variety of protein families because spleen tyrosine kinase is involved in cell division, proliferation, migration and differentiation [12] . Identification of the pathways regulated by spleen tyrosine kinase or the regulation of spleen tyrosine kinase expression in non-haematopoietic cells will provide insights into its roles in tumourigenesis, progression and metastasis.
The area under the ROC curve of VEGF-C and spleen tyrosine kinase was 0.728 and 0.151, respectively. Plotting in the manner of Fig. 2 is a convenient way of choosing their threshold values by calibrating the desired combination of sensitivity and specificity. The combination of a high sensitivity and specificity was obtained using a cut-off value of 1842.2 pg/ml VEGF-C or 3555.8 pg/ml spleen tyrosine kinase, which could be used as a threshold for predicting patients with or without lymph node metastases.
In summary, patients with oesophageal squamous cell carcinoma had significantly elevated serum VEGF-C and decreased spleen tyrosine kinase compared with those of healthy subjects. Furthermore, serum VEGF-C and spleen tyrosine kinase levels are associated with lymph node metastasis, tumour size and extension of primary oesophageal squamous cell carcinoma. Detecting the serum concentration of VEGF-C and spleen tyrosine kinase by enzyme-linked immunosorbent assays can provide a precise evaluation of lymph node metastasis in patients with oesophageal squamous cell carcinoma. Future studies are required to elucidate the mechanisms by which spleen tyrosine kinase and VEGF-C regulate lymph node metastasis in oesophageal squamous cell carcinoma.
